Business
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace.
About this update from Odyssey Health Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace\r\n \r\n \r\n\r\n\r\nOdyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace\r\nOdyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck®\r\n\r\n\r\n\r\n\r\n\r\nLAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through its subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions. The BreastCheck® test can be done at home and takes just 15 minutes. The results are immediate and BreastCheck® has been proven to be a reliable guide in the first stage identification of potential breast abnormalities. While BreastCheck® is not a replacement for a mammogram, it is an effective first line screening device. The technology behind BreastCheck® is FDA registered in the United States, and it is also registered with the relevant regulatory authorities in the European Union and the United Kingdom. “This is a major step forward in our medical device portfolio. Early detection has significantly increased breast cancer survival rates in recent years. It is estimated that this year 317,000 new cases of invasive breast cancer will be diagnosed in women in the United States. Statistics show that 1 in 8 women in the United States will develop breast cancer in their lifetime,” said Michael Redmond, CEO of Odyssey. “The breast cancer diagnostics market is a rapidly growing sector, currently valued in the low tens of billions of dollars depending on what is included, with forecasts to double, or more, over the next 8-10 years. Growth is being driven by technological advances, such as imaging, AI, genomics, the rising incidence of breast cancer globally, greater emphasis on early detection, and expanding healthcare access especially in emerging markets.” “We expect to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking o...